Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus W Koch

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Neurology|October 30, 2021
Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?Gary R Cutter, Marcus W Koch
The Cochrane Database of Systematic Reviews|October 13, 2009
Oxcarbazepine versus carbamazepine monotherapy for partial onset seizuresMarcus W Koch, Susanne Kl Polman
Neurology|October 28, 2022
Tumor Necrosis Factor α Blockers and the Risk of Multiple SclerosisEva M M Strijbis, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 6, 2021
An enrichment strategy for clinical trials in SPMSMarcus W Koch, Luanne Metz, Gary Cutter
Nature Reviews. Neurology|November 21, 2012
Epigenetic changes in patients with multiple sclerosisMarcus W Koch, Luanne M Metz, Olga Kovalchuk
Trends in Molecular Medicine|November 17, 2012
Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosisMarcus W Koch, Luanne M Metz, Olga Kovalchuk
Journal of the Neurological Sciences|October 16, 2007
Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disordersJacques De Keyser, Jop P Mostert, Marcus W Koch
Neurology|February 27, 2019
Clinical Reasoning: A pregnant woman with chin numbnessAlexander J Arnold, Gabriela S Gilmour, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 14, 2019
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data setsMarcus W Koch, Jop Mostert, Bernard Uitdehaag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2021
A comparison of clinical outcomes in PPMS in the INFORMS original trial data setMarcus W Koch, Jop P Mostert, Bernard Uitdehaag, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Neurology|October 30, 2021
Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?Gary R Cutter, Marcus W Koch
The Cochrane Database of Systematic Reviews|October 13, 2009
Oxcarbazepine versus carbamazepine monotherapy for partial onset seizuresMarcus W Koch, Susanne Kl Polman
Neurology|October 28, 2022
Tumor Necrosis Factor α Blockers and the Risk of Multiple SclerosisEva M M Strijbis, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 6, 2021
An enrichment strategy for clinical trials in SPMSMarcus W Koch, Luanne Metz, Gary Cutter
Nature Reviews. Neurology|November 21, 2012
Epigenetic changes in patients with multiple sclerosisMarcus W Koch, Luanne M Metz, Olga Kovalchuk
Trends in Molecular Medicine|November 17, 2012
Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosisMarcus W Koch, Luanne M Metz, Olga Kovalchuk
Journal of the Neurological Sciences|October 16, 2007
Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disordersJacques De Keyser, Jop P Mostert, Marcus W Koch
Neurology|February 27, 2019
Clinical Reasoning: A pregnant woman with chin numbnessAlexander J Arnold, Gabriela S Gilmour, Marcus W Koch
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 14, 2019
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data setsMarcus W Koch, Jop Mostert, Bernard Uitdehaag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 19, 2021
A comparison of clinical outcomes in PPMS in the INFORMS original trial data setMarcus W Koch, Jop P Mostert, Bernard Uitdehaag, et al.
Pageof 6